Savant Capital, LLC Biocryst Pharmaceuticals Inc Transaction History
Savant Capital, LLC
- $11.7 Billion
- Q3 2024
A detailed history of Savant Capital, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Savant Capital, LLC holds 22,062 shares of BCRX stock, worth $169,877. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,062Holding current value
$169,877% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$156 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$154 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$91.4 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$70 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$68.1 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.43B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...